According to the top vaccine researcher at the US Walter Reed Army Institute of Research, scientists at the institute expect to know in the next few days if there's a concern that the COVID-19 vaccines might not work against a mutated variant of the virus that's rapidly spreading in parts of England, CNN reported on Monday.
Dr Nelson Michael, director of the Centre for Infectious Diseases Research at the Walter Reed Army Institute of Research, said that the Walter Reed scientists still expect the COVID-19 vaccine will be effective against this new virus variant.
Reportedly, on 17 December 2020, the Walter Reed team started examining genetic sequences of the new UK variant posted online by British researchers, with a computer analysis being done as a first step.
Michael said: "The computer analysis will allow us to gauge how much concern we should have", adding, "Other teams around the world are doing this analysis, too."
If the computer analysis shows there's a concern, then studies would need to be done in the laboratory and in animals to more definitively determine if the vaccine will work on this variant, CNN added.
Zura Bio announces global Phase 2 TibuSURE trial for systemic sclerosis treatment
Eli Lilly and Co receives approval from FDA for Zepbound
YolTech Therapeutics updates data from Phase I/IIa clinical trial of YOLT-201
AstraZeneca's Tagrisso gains EU approval for advanced lung cancer treatment
Novo Nordisk's CagriSema shows superior weight loss in obesity trial
GSK's Jemperli-Zejula combination shows promise in ovarian cancer
Sapience Therapeutics' ST316 receives US FDA Orphan Drug Designation
Ionis Pharmaceuticals' TRYNGOLZA receives US FDA approval
BioArctic licenses PyroGlu-Aβ antibody programme to Bristol Myers Squibb
Thor Medical signs supply deal with AdvanCell
MOBILion Systems collaborates with Dr Oliver Schmitz to enhance metabolomics analysis
Abilita and Orion partner on antibody therapeutics for oncology and pain
Pharus Diagnostics unveils liquid biopsy test for early pancreatic cancer detection
Mendus reports positive topline data from ovarian cancer trial